Valeant Pharmaceuticals International Inc. (VRX: Quote,VRX.TO: Quote) announced that it has signed an agreement to acquire certain assets from Atlantis Pharma, a branded generics pharmaceutical company located in Mexico with a broad product portfolio, including products in the gastro, analgesics and anti-inflammatory therapeutic categories, for approximately $71 million.
The acquired assets' total revenue in 2011 was approximately $26 million and is expected to deliver double digit growth in 2012. The transaction is expected to close in the second quarter, subject to certain closing conditions including regulatory approvals, and is expected to be immediately accretive.
Click here to receive FREE breaking news email alerts for Valeant Pharmaceuticals International and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org